Amylyx Pharmaceuticals Stock Earnings Reports

Amylyx reported that Q1 2026 was focused on executing the pivotal Phase III LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH). The trial finished enrollment and dosing (last participant dosed in late March) and the company remains on track for a top-line readout in Q3 2026. Amylyx is concurrently drafting NDA materials and advancing launch readiness with hires across commercial, market access and medical affairs to support a potential 2027 approval and commercialization. They launched a U.S. expanded access program (up to 250 adults) to provide avexitide for eligible patients. Commercial research estimates ~160,000 people in the U.S. with PBH after common bariatric surgeries; claims work and site validation support that sizing. Other pipeline updates: AMX0318 (long-acting GLP-1 receptor antagonist) is in IND-enabling studies targeting a 2027 IND; AMX0035 (Wolfram syndrome) longer-term (week 96) data expected at an upcoming meeting; AMX0114 (ALS ASO) completed enrollment of Cohort 2 and early biomarker data from Cohort 1 will be presented at ENCALS in June. Financials: cash and marketable securities were $279.8M at quarter end, which management says funds operations into 2028 and covers key milestones (LUCIDITY top line, potential FDA approval, potential 2027 launch). Q1 operating expenses were $43.8M (R&D up due to avexitide development; SG&A modestly higher due to launch prep). Additional contextual developments include anticipated ICD-10 code for PBH effective Oct 1, 2026, which management believes will aid recognition and tracking of the condition.